Healthcare Review: Chelsea Therapeutics International Ltd, Idera Pharmaceuticals Inc, Ampio Pharmaceuticals Inc, Horizon Pharma Inc., Arrowhead Research Corp. Print E-mail
By Staff and Wire Reports   
Thursday, 08 May 2014 12:37
U.S. stock index futures were little changed on Thursday, ahead of data on the labor market and as earnings season began to wind down. Shares of Chelsea Therapeutics International Ltd. ($CHTP) are trading 30.60% higher at $6.53. The company has entered into a definitive agreement to be acquired by H. Lundbeck A/S (Lundbeck) (LUN.CO) (LUN DC) (HLUYY), a global pharmaceutical company that specializes in brain diseases.

Idera Pharmaceuticals Inc ($IDRA)’s shares jumped 5.62% to $2.63 after the company announced that it has entered into an agreement with Abbott (ABT), the global healthcare company, for the development of an in vitro companion diagnostic test for use in Idera’s clinical development programs to treat certain genetically defined forms of B-cell lymphoma with IMO-8400.

Ampio Pharmaceuticals Inc ($AMPE)’s shares soared 16.87% to $6.79. Citigroup Inc. assumed coverage on shares of Ampio Pharmaceuticals ($AMPE) in a research note issued on Thursday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock.

Horizon Pharma Inc ($HZNP)’s shares added 4.18% to $13.96. Horizon Pharma, Inc. operates as a biopharmaceutical company. It is focused on developing and commercializing medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases.

Arrowhead Research Corp ($ARWR)’s shares gained 4.09% to $10.19. Recently, Zacks reaffirmed their outperform rating on shares of Arrowhead Research Corp (ARWR) in a report issued on Tuesday, Analyst Ratings Network.com reports. They currently have an $18.75 target price on the stock.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter